BR112019018648A2 - Inibidores de jak contendo uma amida heterocíclica com 4 membros - Google Patents

Inibidores de jak contendo uma amida heterocíclica com 4 membros Download PDF

Info

Publication number
BR112019018648A2
BR112019018648A2 BR112019018648-4A BR112019018648A BR112019018648A2 BR 112019018648 A2 BR112019018648 A2 BR 112019018648A2 BR 112019018648 A BR112019018648 A BR 112019018648A BR 112019018648 A2 BR112019018648 A2 BR 112019018648A2
Authority
BR
Brazil
Prior art keywords
compounds
starch
member heterocyclic
jak inhibitors
inhibitors containing
Prior art date
Application number
BR112019018648-4A
Other languages
English (en)
Portuguese (pt)
Inventor
R. Fatheree Paul
E.L. BRANDT Gary
Smith Cameron
D.E. Sullivan Steven
Jean Van Orden Lori
A. Kleinschek Melanie
D. CRATER Glenn
Original Assignee
Theravance Biopharma R&D Ip, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip, Llc filed Critical Theravance Biopharma R&D Ip, Llc
Publication of BR112019018648A2 publication Critical patent/BR112019018648A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
BR112019018648-4A 2017-03-09 2018-03-08 Inibidores de jak contendo uma amida heterocíclica com 4 membros BR112019018648A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762469073P 2017-03-09 2017-03-09
US62/469,073 2017-03-09
PCT/US2018/021489 WO2018165392A1 (en) 2017-03-09 2018-03-08 Jak inhibitors containing a 4-membered heterocyclic amide

Publications (1)

Publication Number Publication Date
BR112019018648A2 true BR112019018648A2 (pt) 2020-06-16

Family

ID=61683956

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112019018648-4A BR112019018648A2 (pt) 2017-03-09 2018-03-08 Inibidores de jak contendo uma amida heterocíclica com 4 membros
BR112019018649A BR112019018649A2 (pt) 2017-03-09 2018-03-08 inibidores jak derivados da fusão de imidazopiperidina

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112019018649A BR112019018649A2 (pt) 2017-03-09 2018-03-08 inibidores jak derivados da fusão de imidazopiperidina

Country Status (20)

Country Link
US (10) US10208040B2 (enExample)
EP (2) EP3592742B1 (enExample)
JP (2) JP6974487B2 (enExample)
KR (2) KR102533646B1 (enExample)
CN (2) CN110461839B (enExample)
AR (2) AR111241A1 (enExample)
AU (2) AU2018231035B2 (enExample)
BR (2) BR112019018648A2 (enExample)
CA (1) CA2997772A1 (enExample)
DK (1) DK3592742T3 (enExample)
EA (2) EA037261B1 (enExample)
ES (1) ES2882186T3 (enExample)
IL (2) IL268689B2 (enExample)
MX (2) MX388749B (enExample)
PH (2) PH12019501941A1 (enExample)
PT (1) PT3592742T (enExample)
SG (2) SG11201907544VA (enExample)
TW (2) TWI779016B (enExample)
WO (2) WO2018165392A1 (enExample)
ZA (2) ZA201905585B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016350816B2 (en) 2015-11-03 2020-06-25 Theravance Biopharma R&D Ip, Llc JAK kinase inhibitor compounds for treatment of respiratory disease
PT3371185T (pt) * 2015-11-03 2020-12-28 Topivert Pharma Ltd Derivados de 4,5,6,7-tetrahidro-1h-imidazo[4,5-c]piridina e 1,4,5,6,7,8-hexahidroimidazo[4,5-d]azepina como inibidores de janus quinase
EA037261B1 (ru) * 2017-03-09 2021-03-01 ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи Ингибиторы jak, содержащие 4-членный гетероциклический амид
CA3059785A1 (en) 2017-05-01 2018-11-08 Theravance Biopharma R&D Ip, Llc Methods of treatment using a jak inhibitor compound
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
SI3837258T1 (sl) 2018-09-04 2024-09-30 Theravance Biopharma R&D Ip, Llc Dimetil amino azetidin amidi, ki se uporabljajo kot JAK zaviralci
CA3108848A1 (en) 2018-09-04 2020-03-12 Theravance Biopharma R&D Ip, Llc Process for preparing jak inhibitors and intermediates thereof
ES2955717T3 (es) 2018-09-04 2023-12-05 Theravance Biopharma R&D Ip Llc Amidas heterocíclicas de 5 a 7 elementos como inhibidores de JAK
EP3853229A1 (en) * 2018-10-29 2021-07-28 Theravance Biopharma R&D IP, LLC 2-azabicyclo hexane compound as jak inhibitor
JP7514025B2 (ja) * 2019-02-25 2024-07-10 ホーナン メディノ ファーマシューティカル テクノロジー カンパニー リミテッド Ｊａｋ阻害剤化合物及びその使用
MX2021010545A (es) 2019-03-05 2021-11-17 Incyte Corp Inhibidores de la vía de cinasa janus 1 (jak1) para el tratamiento de la disfunción crónica del aloinjerto pulmonar.
US11697648B2 (en) * 2019-11-26 2023-07-11 Theravance Biopharma R&D Ip, Llc Fused pyrimidine pyridinone compounds as JAK inhibitors
WO2021136345A1 (zh) * 2019-12-30 2021-07-08 路良 Jak抑制剂化合物及其用途
TW202144343A (zh) * 2020-03-02 2021-12-01 美商施萬生物製藥研發 Ip有限責任公司 Jak抑制劑化合物之結晶水合物
EP3944859A1 (en) 2020-07-30 2022-02-02 Assistance Publique Hôpitaux de Paris Method for treating immune toxicities induced by immune checkpoint inhibitors
WO2022178215A1 (en) * 2021-02-19 2022-08-25 Theravance Biopharma R&D Ip, Llc Amino amide tetrahydro imidazo pyridines as jak inhibitors
EP4359402A1 (en) 2021-06-25 2024-05-01 Theravance Biopharma R&D IP, LLC Imidazolo indazole compounds as jak inhibitors
KR20230092805A (ko) * 2021-12-17 2023-06-26 주식회사 대웅제약 (2R, 3S)-2-(3-(4,5-디클로로-1H-벤조[d]이미다졸-1-일)프로필)피페리딘-3-올의 신규한 산부가염 및 결정형
CN117658852A (zh) * 2023-11-15 2024-03-08 西北工业大学 取代苯氧乙酰肼类化合物及其制备方法和作为stat3的抗炎抑制剂的应用
WO2025157904A1 (en) * 2024-01-24 2025-07-31 Kiox Pharmaceuticals Aps Inhalable formulations of ruxolitinib, methods of manufacture and uses thereof
CN118903009B (zh) * 2024-10-11 2025-01-21 江苏长泰药业股份有限公司 一种调节呼吸道微生态的丙酮酸钠气雾剂及其制备方法和应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
AU2004259012C1 (en) 2003-07-23 2012-08-02 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
US20050090529A1 (en) 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US7884109B2 (en) 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
JP2010111624A (ja) 2008-11-06 2010-05-20 Shionogi & Co Ltd Ｔｔｋ阻害作用を有するインダゾール誘導体
WO2010114971A1 (en) 2009-04-03 2010-10-07 Sepracor Inc. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
WO2011084486A1 (en) 2009-12-21 2011-07-14 Epitherix, Llc 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
EP2338888A1 (en) * 2009-12-24 2011-06-29 Almirall, S.A. Imidazopyridine derivatives as JAK inhibitors
US8575336B2 (en) * 2011-07-27 2013-11-05 Pfizer Limited Indazoles
EP2771340B1 (en) 2011-10-25 2016-04-13 Sanofi 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
ME02883B (me) 2013-12-05 2018-04-20 Pfizer PIROLO[2,3-d]PIRIMIDINIL-, PIROLO[2,3-b]PIRAZINIL- I PIROLO[2,3-d] PIRIDINILAKRILAMIDI
CR20160525A (es) 2014-05-14 2016-12-20 Pfizer Pirazolopiridinas y pirazolopirimidinas
WO2016026078A1 (en) 2014-08-19 2016-02-25 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as erk inhibitors
KR101663277B1 (ko) 2015-03-30 2016-10-06 주식회사 녹십자 TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물
AU2016350816B2 (en) 2015-11-03 2020-06-25 Theravance Biopharma R&D Ip, Llc JAK kinase inhibitor compounds for treatment of respiratory disease
US10851097B2 (en) 2015-11-03 2020-12-01 Topivert Pharma Limited 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
PT3371185T (pt) * 2015-11-03 2020-12-28 Topivert Pharma Ltd Derivados de 4,5,6,7-tetrahidro-1h-imidazo[4,5-c]piridina e 1,4,5,6,7,8-hexahidroimidazo[4,5-d]azepina como inibidores de janus quinase
EA037261B1 (ru) * 2017-03-09 2021-03-01 ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи Ингибиторы jak, содержащие 4-членный гетероциклический амид
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
CA3059785A1 (en) 2017-05-01 2018-11-08 Theravance Biopharma R&D Ip, Llc Methods of treatment using a jak inhibitor compound
KR20200003121A (ko) 2017-05-01 2020-01-08 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Jak 저해제 화합물의 결정형
KR102032418B1 (ko) 2017-06-15 2019-10-16 한국화학연구원 접합 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 브루톤티로신 키나제 활성 관련 질환의 예방 또는 치료용 약학적 조성물
ES2955717T3 (es) 2018-09-04 2023-12-05 Theravance Biopharma R&D Ip Llc Amidas heterocíclicas de 5 a 7 elementos como inhibidores de JAK
CA3108848A1 (en) 2018-09-04 2020-03-12 Theravance Biopharma R&D Ip, Llc Process for preparing jak inhibitors and intermediates thereof
SI3837258T1 (sl) 2018-09-04 2024-09-30 Theravance Biopharma R&D Ip, Llc Dimetil amino azetidin amidi, ki se uporabljajo kot JAK zaviralci

Also Published As

Publication number Publication date
JP6974487B2 (ja) 2021-12-01
AR111241A1 (es) 2019-06-19
PH12019501941A1 (en) 2020-07-06
US20190337945A1 (en) 2019-11-07
JP2020510010A (ja) 2020-04-02
US20210269436A1 (en) 2021-09-02
KR102526764B1 (ko) 2023-04-27
US20230063643A1 (en) 2023-03-02
US20180258087A1 (en) 2018-09-13
BR112019018649A2 (pt) 2020-04-07
SG11201907544VA (en) 2019-09-27
AU2018231035B2 (en) 2021-09-09
IL268689B (en) 2022-10-01
MX2019010539A (es) 2019-10-21
ES2882186T3 (es) 2021-12-01
TW201837037A (zh) 2018-10-16
CN110382498B (zh) 2022-07-12
NZ756823A (en) 2021-04-30
IL268689B2 (en) 2023-02-01
TWI754019B (zh) 2022-02-01
US20180258088A1 (en) 2018-09-13
AR111242A1 (es) 2019-06-19
MX388749B (es) 2025-03-11
US10392386B2 (en) 2019-08-27
MX2019010541A (es) 2019-10-21
WO2018165392A1 (en) 2018-09-13
ZA201905618B (en) 2021-05-26
US20220289737A1 (en) 2022-09-15
KR20190127798A (ko) 2019-11-13
EA037748B1 (ru) 2021-05-18
PT3592742T (pt) 2021-07-30
IL268689A (en) 2019-10-31
US11878977B2 (en) 2024-01-23
US11453668B2 (en) 2022-09-27
JP2020510015A (ja) 2020-04-02
CN110461839A (zh) 2019-11-15
SG11201907840RA (en) 2019-09-27
CN110382498A (zh) 2019-10-25
EA201992128A1 (ru) 2020-01-29
EA201992126A1 (ru) 2020-02-05
US10519153B2 (en) 2019-12-31
US11254669B2 (en) 2022-02-22
WO2018165395A1 (en) 2018-09-13
KR102533646B1 (ko) 2023-05-17
JP7134990B2 (ja) 2022-09-12
TW201840560A (zh) 2018-11-16
US20200181141A1 (en) 2020-06-11
EA037261B1 (ru) 2021-03-01
US10550118B2 (en) 2020-02-04
CA2997772A1 (en) 2018-09-09
EP3592743A1 (en) 2020-01-15
US20190119275A1 (en) 2019-04-25
US10954237B2 (en) 2021-03-23
IL268679A (en) 2019-10-31
EP3592742A1 (en) 2020-01-15
AU2018231035A1 (en) 2019-09-05
AU2018231032A1 (en) 2019-09-05
US10196393B2 (en) 2019-02-05
AU2018231032B2 (en) 2021-08-19
IL268679B (en) 2021-10-31
MX388750B (es) 2025-03-20
EP3592742B1 (en) 2021-05-19
ZA201905585B (en) 2020-05-27
US10208040B2 (en) 2019-02-19
US11667637B2 (en) 2023-06-06
DK3592742T3 (da) 2021-08-09
US20190127371A1 (en) 2019-05-02
CN110461839B (zh) 2022-08-23
PH12019501985A1 (en) 2020-10-05
AU2018231032A8 (en) 2019-10-17
US20200216447A1 (en) 2020-07-09
KR20190127796A (ko) 2019-11-13
TWI779016B (zh) 2022-10-01

Similar Documents

Publication Publication Date Title
BR112019018648A2 (pt) Inibidores de jak contendo uma amida heterocíclica com 4 membros
BR112018072168A2 (pt) compostos derivados da pirimidina como inibidores da quinase jak
MY208632A (en) Novel benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors
EA202190681A1 (ru) Амиды диметиламиноазетидина в качестве jak ингибиторов
EA202190686A1 (ru) 5-7-членные гетероциклические амиды в качестве ингибиторов jak
GEAP202515818A (en) Amino quinazoline derivatives as p2x3 inhibitors
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
TN2018000043A1 (en) Novel 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as prmt5 inhibitors
BR112018008966A2 (pt) compostos inibidores de jak quinase para o tratamento de doença respiratória
EA202090413A1 (ru) Пиразоло- и триазолобициклические соединения в качестве ингибиторов jak киназы
EA202090688A1 (ru) Бис-амидные соединения, активирующие саркомер, и варианты их применения
CR20200263A (es) Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5
PH12021551280A1 (en) Heteroaromatic compounds as vanin inhibitors
PH12021550269A1 (en) Heteroaromatic compounds as vanin inhibitors
SA519401322B1 (ar) مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2
MX2019014876A (es) Compuestos heteroaromaticos como inhibidores de vanina.
MX2021006489A (es) Compuestos heteroaromaticos como inhibidores de vanina.
MX2018008307A (es) Derivado de ascoclorina y uso del mismo como activador de proteina cinasa activada por adenosin monofosfato (ampk).
BR112018015191A2 (pt) compostos de 6,7-di-hidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxamida
MX2023004008A (es) Derivados de tetrazol como inhibidores de trpa1.
MX2021006490A (es) Compuestos heteroaromaticos como inhibidores de vanina.
PH12021550258A1 (en) Cdk8/19 inhibitors
MX385475B (es) Derivados de piridoquinazolina eficaces como inhibidores de proteina quinasa
MX2019014438A (es) Derivados de acidos carboxilicos eficaces como inhibidores de la proteina quinasa.

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2822 DE 04/02/2025.